These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16035650)

  • 1. Atheroprotective properties of nifedipine.
    Yamagishi S; Takeuchi M
    Int J Tissue React; 2005; 27(2):63-7. PubMed ID: 16035650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha.
    Yamagishi S; Inagaki Y; Abe R; Kikuchi S; Sasaki N; Takeuchi M
    Drugs Exp Clin Res; 2003; 29(4):141-5. PubMed ID: 15018304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells.
    Yamagishi S; Kikuchi S; Takenaka K; Takeuchi M
    Drugs Exp Clin Res; 2005; 31(5-6):221-6. PubMed ID: 16425979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of nifedipine on atherosclerosis.
    Yamagishi S; Nakamura K; Takenaka K; Matsui T; Inoue H
    Curr Pharm Des; 2006; 12(12):1543-7. PubMed ID: 16611134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2007; 68(5):1096-8. PubMed ID: 17097822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2009 Jul; 385(2):269-72. PubMed ID: 19460355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
    Yamagishi S; Nakamura K; Matsui T
    Curr Med Chem; 2008; 15(2):172-7. PubMed ID: 18220772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiperoxidative actions of calcium antagonists and atherogenesis.
    Henry PD
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S6-10. PubMed ID: 1723459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation.
    Passacquale G; Desideri G; Croce G; Murgo S; Mancarelli MM; Zazzeroni F; Alesse E; Ferri C
    J Hypertens; 2008 Apr; 26(4):737-46. PubMed ID: 18327084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.
    Oshima T; Ozono R; Yano Y; Higashi Y; Teragawa H; Miho N; Ishida T; Ishida M; Yoshizumi M; Kambe M
    Hypertens Res; 2005 Nov; 28(11):889-94. PubMed ID: 16555577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells.
    Chen J; Huang L; Song M; Yu S; Gao P; Jing J
    J Cardiovasc Pharmacol; 2009 May; 53(5):359-67. PubMed ID: 19276989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nifedipine on endothelial function in normotensive smokers: potential contribution of increase in circulating hepatocyte growth factor.
    Yamasaki K; Aoki M; Makino H; Hashiya N; Shimizu H; Ohishi M; Ogihara T; Morishita R
    J Hum Hypertens; 2004 Oct; 18(10):701-5. PubMed ID: 15071489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium antagonists: current and future applications based on new evidence. Effects of calcium channel blockers on oxidative stress].
    Nishiyama A; Nakano D; Hitomi H
    Clin Calcium; 2010 Jan; 20(1):38-44. PubMed ID: 20048432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcium antagonists: current and future applications based on new evidence. Calcium antagonists and diabetes].
    Yamagishi S
    Clin Calcium; 2010 Jan; 20(1):77-82. PubMed ID: 20048437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats.
    Liu LL; Li QX; Xia L; Li J; Shao L
    Toxicology; 2007 Feb; 231(1):81-90. PubMed ID: 17234320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium antagonists and atherosclerosis.
    Betz E; Weiss HD; Heinle H; Fotev Z
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S71-5. PubMed ID: 1725009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of calcium channel blockers in atherosclerosis and cardiovascular event and oxidative vascular damage].
    Fujino T; Sumitomo K; Hasebe N; Kikuchi K
    Clin Calcium; 2004 Jan; 14(1):119-27. PubMed ID: 15576967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Calcium antagonists and endothelial function].
    Yasuda O; Kawamoto H; Yokoi T; Rakugi H; Ogihara T
    Clin Calcium; 2005 Oct; 15(10):1663-8. PubMed ID: 16199912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revival of nifedipine, a dihydropyridine-based calcium blocker.
    Yamagishi S; Nakamura K
    Med Hypotheses; 2007; 68(3):565-7. PubMed ID: 17011717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.